Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.
about
Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor functionInvestigation on quantitative structure activity relationships and pharmacophore modeling of a series of mGluR2 antagonistsPositive allosteric modulators to peptide GPCRs: a promising class of drugsNovel Allosteric Modulators of G Protein-coupled ReceptorsAllosteric modulation of metabotropic glutamate receptors.NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.Critical design issues in the targeted molecular imaging of cell surface receptors.Structure and ligand recognition of class C GPCRsAction of molecular switches in GPCRs--theoretical and experimental studies.Iterative experimental and virtual high-throughput screening identifies metabotropic glutamate receptor subtype 4 positive allosteric modulators.Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5).Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders.mGluR5 positive allosteric modulation enhances extinction learning following cocaine self-administration.Allosteric regulation of pathologic angiogenesis: potential application for angiogenesis-related blindness.Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family.Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach.Discovery of Small-Molecule Modulators of the Human Y4 ReceptorEffects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophreniaGroup I metabotropic glutamate receptor-mediated gene transcription and implications for synaptic plasticity and diseases.Translational Concepts of mGluR5 in Synaptic Diseases of the BrainModulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test.A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signalingProbing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersAlteration by p11 of mGluR5 localization regulates depression-like behaviors.Linking receptor activation to changes in Sw I and II of Gα proteins.Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses.Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism.Metabotropic glutamate receptor 5 negative modulation in phase I clinical trial: potential impact of circadian rhythm on the neuropsychiatric adverse reactions-do hallucinations matter?Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.Approaches for probing allosteric interactions at 7 transmembrane spanning receptors.Mavoglurant as a treatment for Parkinson's disease.Allosteric therapies for lung cancer.Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes.Tetracycline-based system for controlled inducible expression of group III metabotropic glutamate receptors.Structural insight to mutation effects uncover a common allosteric site in class C GPCRs
P2860
Q24338263-26F592A0-280D-4775-AC8C-3B32F03A6FA8Q24635165-228130CA-C2BF-486F-835A-D1E5AB5078F1Q27002663-A92D6DDD-AA65-4036-B0E7-64E816E6E77DQ28081112-344EEA2A-E4E3-406A-9E3C-C29DD39E5112Q30448534-D2F36D9F-63C2-4C40-BC0F-5688B9E2544DQ30465008-232BDCB4-E5BF-4652-8A81-FE8D819F7D2EQ30899036-EA846FE9-96B3-440C-A7B0-3DB836AF65EBQ33828724-1BC8698D-723B-4DE2-997C-A29F732FE581Q34251407-D62D1BA7-993A-4510-ADF5-E00EF83DF10BQ34271873-BC93A628-C646-444D-854E-1FC8314C0905Q34317403-854BF97F-023B-4DAF-9F43-BDEEF7E5A28FQ34399823-80F3AC50-9412-4091-8383-A99A5E86A71CQ34761363-CF59CC67-5CB5-4170-9436-5314B5797316Q34775016-EE89D409-AF66-4AE7-AB24-007EFAB506DFQ35084192-EC497E62-5C96-41B8-8C64-E1472CDB4CE0Q35188148-5C92BF27-AB2E-4934-9FA1-9858456317FDQ35529175-335E37DD-D8C9-45A5-B1E4-07B596F8AAC5Q35765639-2CB3C4C7-EBFE-43BF-9B04-E727C824DB73Q36050350-BFCB428A-3876-4967-B651-DD05494CE2E1Q36052391-3973CA57-0AED-49C4-A162-82AF22B5D9E4Q36361892-3EC05405-1CD2-4403-9412-DE8C42A3D388Q36424785-C423868C-A7D6-4BDD-BC98-7F720E1D9D8EQ36598822-ED0C0AF0-BDC2-4F8B-AC15-6595DE51298BQ36675499-BACF174C-3FF3-4C26-A53D-7EF41310BAF2Q36717066-396EFCA1-7DF7-4625-9107-1C60DA3DBC59Q36776760-71039823-6B7D-4E7B-ABD4-EEF4FF817230Q36799584-824E9019-281D-4A77-AB5E-D7477D214DC6Q37002871-3A00BA37-72DB-4E22-8729-4E3B3504BA9CQ37053797-BFE95D83-C8FE-4D25-AA04-962A4960D861Q37067455-33A79560-26D1-4919-8D57-C6157B3C69C4Q37068738-B3324FEA-7411-45DC-9EC3-ADB25AAA0518Q37422727-E079DF99-D59E-4BEE-BBC2-170FF8B54FBFQ37651104-DEFE6522-4818-46CB-AC38-6DB05772B5B0Q38031832-A49711CA-869C-4C3E-818B-B9DE60886F39Q38082089-B5539A54-6745-4974-B3B0-4059A0435416Q38222814-7E9E46A5-7EB8-483D-879B-66DDB0CF454EQ38465098-5FE79315-1692-429E-882B-7F75FA011B7CQ38690877-F7A5BB24-ED04-438F-86F7-11AF1AB3D806Q38940608-B5B95BCD-50AB-4F7F-9CF7-AF7F8D017429Q39067605-94C4AF7A-638F-4F6A-9846-262CC12AB864
P2860
Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Allosteric modulation of metab ...... hts and therapeutic potential.
@en
Allosteric modulation of metab ...... hts and therapeutic potential.
@nl
type
label
Allosteric modulation of metab ...... hts and therapeutic potential.
@en
Allosteric modulation of metab ...... hts and therapeutic potential.
@nl
prefLabel
Allosteric modulation of metab ...... hts and therapeutic potential.
@en
Allosteric modulation of metab ...... hts and therapeutic potential.
@nl
P2860
P1433
P1476
Allosteric modulation of metab ...... hts and therapeutic potential.
@en
P2093
Elizabeth N Dong
Karen J Gregory
P2860
P356
10.1016/J.NEUROPHARM.2010.07.007
P577
2010-07-14T00:00:00Z